| Identification | Back Directory | [Name]
Bafetinib | [CAS]
859212-16-1 | [Synonyms]
Ns 187
CS-239
Inno 406
Inno-406
Unii-nvw4Z03I9b
Bafetinib (INNO-406)
INNO 406 - Bafetinib
Bafetinib(INNO 406,NS 187)
NS-187; BAFETINIB; INNO406
(S)-N-(3-([4,5'-bipyriMidin]-2-ylaMino)-4-Methylphenyl)-4-((3-(diMethylaMino)pyrrolidin-1-yl)Methyl)-3-(trifluoroMethyl)benzaMide
N-[3-([4,5'-BipyriMidin]-2-ylaMino)-4-Methylphenyl]-4-[[(3S)-3-(diMethylaMino)-1-pyrrolidinyl]Methyl]-3-(trifluoroMethyl)benzaMide
Benzamide, N-(3-((4,5'-bipyrimidin)-2-ylamino)-4-methylphenyl)-4-(((3S)-3-(dimethylamino)-1-pyrrolidinyl)methyl)-3-(trifluoromethyl)-
4-[[(3S)-3-Dimethylaminopyrrolidin-1-yl]methyl]-N-[4-methyl-3-[(4-pyrimidin-5-ylpyrimidin-2-yl)amino]phenyl]-3-(trifluoromethyl)benzamide
(S)-4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-N-(4-methyl-3-(4-(pyrimidin-5-yl)pyrimidin-2-ylamino)phenyl)-3-(trifluoromethyl)benzamide
Bafetinib N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[(3S)-3-(dimethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)benzamide | [Molecular Formula]
C30H31F3N8O | [MDL Number]
MFCD18633200 | [MOL File]
859212-16-1.mol | [Molecular Weight]
576.62 |
| Chemical Properties | Back Directory | [Melting point ]
166-168°C | [density ]
1.36±0.1 g/cm3(Predicted) | [storage temp. ]
Refrigerator | [solubility ]
DMSO:42.0(Max Conc. mg/mL);72.84(Max Conc. mM) | [form ]
A crystalline solid | [pka]
12.72±0.70(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Description]
Bcr-Abl, a fusion protein with deregulated tyrosine kinase activity, is highly expressed in chronic myelogenous leukemia (CML). Bafetinib is a rationally developed tyrosine kinase inhibitor based on the chemical structure of imatinib (Item No. 13139), with modifications added to improve binding and potency against Bcr-Abl kinase (IC50 = 5.8 nM).1 It is 25- to 55-fold more potent than imatinib in vitro and ≥10-fold more potent in vivo.1 Bafetinib inhibits 12 out of the 13 most frequent imatinib-resistant Bcr-Abl point mutations, but not the T315I mutation and also targets the Src family kinase Lyn (IC50 = 19 nM), which has been associated with resistance to imatinib in CML.1 | [Chemical Properties]
Pale Yellow Solid | [Uses]
A substituted benzamide derivative structurally related to STI-571 (Imatinib Mesylate). It was identified as highly potent Bcr-Abl kinase inhibitor. |
|
|